Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Mammoth deal with GSK could lead to home COVID-19 test

By Tom Salemi | May 20, 2020

CRISPR startup Mammoth Biosciences will partner with GlaxoSmithKline’s (NYSE:GSK) consumer healthcare division to develop a home-based diagnostic capable of detecting active SARS-CoV-2, the novel coronavirus that causes COVID-19.

The collaboration will use Mammoth Biosciences’ CRISPR-based Detectr  platform to design “guide-RNA” that can identify and signal the presence of viral strands obtained through a simple nasal swab, according to Mammoth Biosciences CEO Trevor Martin.

Martin said he couldn’t speak to the specifics of the deal with GSK.

“This is really a long-term play in the next generation of diagnostics,” he said in an interview with MassDevice. “One of the powers of the CRISPR-based platform is you can switch out the guide-DNA, so over the long term you can imagine using the same platform for a variety of diseases.”

The company intends to file for an FDA emergency use authorization for the test by the end of 2020. If it’s approved, Martin said he can envision the test being sold directly to consumers or through physicians. The test should be able to produce a result in less than 20 minutes.

Based in South San Francisco, Mammoth Biosciences was co-founded by CRISPR pioneer Jennifer Doudna. The company has raised roughly $70 million from investors including Mayfield, NFX, and 8VC, Decheng Capital and individual investors including entrepreneur Brook Byers, Apple CEO Tim Cook and Jeff Huber, founding CEO and vice Chair of GRAIL, Inc.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: GlaxoSmithKline, Mammoth Biosciences
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50